For Lundbeck and Otsuka's PTSD filing, FDA questions Rexulti efficacy after failed phase 3

16th July 2025 Uncategorised 0

The FDA is asking an expert panel to weigh in on “discordant results” from three randomized trials related to Lundbeck and Otsuka’s application for a Rexulti combination regimen in PTSD.

More: For Lundbeck and Otsuka's PTSD filing, FDA questions Rexulti efficacy after failed phase 3
Source: fierce